Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+4.29%
-1.32%
-14.99%
+22.09%
-1.56%
AD
Array Digital Infrastruct
$50.07
Login to see Array Digital Infrastruct (AD) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Chart
$48.34 (+3.58%)
$54.33 (-7.84%)
$54.33 (-7.84%)
$54.33 (-7.84%)
AD has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Low volume
AD overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
AD Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
AD Street view is extremely bullish and have positive views on the near-term outlook
What is AD current stock price?
What are AD stock strengths?
What risks are associated with AD stock?
When is AD next earnings report?
What is AD market cap and volume?
What is AD's current Stock IQ?
Should I buy AD stock right now?
Is AD a Strong Buy right now?
What does a 'Strong Buy' rating mean for AD?
What does a 'Strong Sell' rating mean for AD?
What factors influence AD's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+4.29%
-1.32%
-14.99%
+22.09%
-1.56%
AD
Array Digital Infrastruct
Current Price
$50.07
Stock Insights
Strengths
Earnings are forecast to grow
Login to unlock Array Digital Infrastruct (AD) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$48.34 (+3.58%)
$54.33 (-7.84%)
$54.33 (-7.84%)
$54.33 (-7.84%)
AD Analysts Opinion
AD Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
AD Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
AD Street view is extremely bullish and have positive views on the near-term outlook
AD has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Low volume
AD Latest Analysis
Oversold Conditions For Array Digital Infrastructure (AD). Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which me
Thu Sep 25, 2025
Annovis Appoints Mark Guerin as Chief Financial Officer. MALVERN Pa. Sept. 25 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) (Annovis or the Company) a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimers disease (AD) and Parkinsons disease (PD) today announced the appointment of Mark Guerin CPA CMA CFM as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to sho
Thu Sep 25, 2025
FDA Expands Incytes Opzelura Approval To Treat Atopic Dermatitis In Children. The United States Food and Drug Administration (FDA) on Thursday approved ) announced Opzelura (ruxolitinib) cream 1.5% for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised children two years of age and older whose disease is not well controlled with topical prescription therapies or when those .The FDA approval of the supplemental New Drug Applicat
Fri Sep 19, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings
Leaders